Related Experiment Video
Updated: Aug 19, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Alterations in the omics profiles in mevalonate pathway-inhibited cancer cells
Tomoko Warita1, Nanami Irie2, Yaxuan Zhou2
1Department of Biomedical Sciences, School of Biological and Environmental Sciences, Kwansei Gakuin University, 1 Gakuen Uegahara, Sanda, Hyogo 669-1330, Japan.
Aims:
Statins, cholesterol-lowering drugs, are potential therapeutic agents for inhibiting cancer proliferation. However, the mechanisms that mediate the effects of statins, the homeostatic responses of tumor cells to statin therapy, and the modes underlying the antitumor effects of statins remain unclear.
Main Methods:
To uncover the effects of statins on cancer cells in vitro, we performed transcriptome and metabolome analyses on atorvastatin-treated statin-resistant and statin-sensitive lung cancer cells.
Key Findings:
The results of Gene Ontology terms and pathway enrichment analyses showed that after 24 h of atorvastatin treatment, the expression of cell cycle- and DNA replication-related genes was significantly decreased in the statin-sensitive cancer cells. The results of metabolome analysis showed that the components of polyamine metabolism and purine metabolism, glycolysis, and pentose phosphate pathway were decreased in the statin-sensitive cancer cells.
Significance:
Differences in cellular properties between statin-sensitive and statin-resistant cancer cells revealed additional candidates for therapeutic targets in statin-treated cancer cells and suggested that inhibiting these metabolic pathways could improve efficacy. In conclusion, combining statins with inhibitors of polyamine metabolism (cell proliferation and protein translation), purine metabolism (DNA synthesis), glycolytic system (energy production), and pentose phosphate pathway (antioxidant stress) might enhance the anticancer effects of statins.
Insights
Statins show potential against cancer by affecting cell cycle and DNA replication. Combining statins with metabolic pathway inhibitors may enhance their antitumor effects in lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Statins, cholesterol-lowering drugs, are investigated for their potential to inhibit cancer proliferation.
- Mechanisms of statin action, tumor cell responses, and antitumor effects require further elucidation.
Purpose of the Study:
- To investigate the effects of statins on cancer cells.
- To compare responses between statin-sensitive and statin-resistant lung cancer cells.
Main Methods:
- Transcriptome and metabolome analyses were performed on atorvastatin-treated lung cancer cells.
- Gene Ontology and pathway enrichment analyses were utilized.
Main Results:
- Atorvastatin treatment decreased cell cycle and DNA replication gene expression in statin-sensitive cells.
- Metabolome analysis revealed decreased polyamine, purine metabolism, glycolysis, and pentose phosphate pathways in statin-sensitive cells.
Conclusions:
- Differences between sensitive and resistant cells highlight potential therapeutic targets.
- Inhibiting specific metabolic pathways alongside statins may improve anticancer efficacy.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
MicroRNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation

